Novel Anti-Amyloid Drug Aims to Outperform Current Standards

(MedPage Today) — TORONTO — An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta plaques associated with Alzheimer’s disease, performed so well in a phase Ib/IIa trial that pivotal studies…